Gabapentin has been administered in placebo-controlled studies with a thrice daily (T.I.D.) schedule, because of its short halflife. However, clinical efficacy does not seem strictly related to plasma levels: a twice daily (B.I.D.) schedule might therefore be possible. The aim of our study was to verify if the conversion from a T.I.D. to a B.I.D. regimen affected the efficacy and safety of gabapentin therapy. Out of 171 patients treated with add-on gabapentin, we selected 29 stable responders, who were followed for three months with a T.I.D. schedule and then switched to B.I.D. regimen for further three months. Seizure number, side-effects and trough plasma levels of gabapentin were collected during both periods. Gabapentin mean dose was 2117.2 mg/day. Mean number of seizures/months was: 4.2 at baseline, 1.0 during the T.I.D., and 0.9 during the B.I.D. period. Mean trough plasma level of gabapentin was 5.9 µg/ml during the T.I.D. and 5.2 µg/ml during the B.I.D. period. Twelve side-effects were reported by 11 patients during the T.I.D. and 6 by 5 patients during the B.I.D. period., sedation and vertigo were the most frequent in both. Results of our study suggest that gabapentin can be administered safely and effectively either with a T.I.D. and a B.I.D. regimen.
INTRODUCTION
Gabapentin (GBP) is an anticonvulsant with a favourable pharmacokinetic profile, characterized by no binding to plasma proteins and no interactions with other antiepileptic drugs (AEDs).
The precise mechanism of the antiepileptic action of GBP is still unknown. Although structurally related to the gamma aminobutyric acid (GABA) neurotransmitter, GBP does not bind to GABA receptors and does not influence neural uptake of GABA or have any significant effect on GABA transaminase activity. Possible mechanisms of action include biochemical effects enhancing the ratio of GABA to glutamate inside the neurons and the enhancement of nonsynaptic GABA release 1 . These cellular actions of GBP are not completely understood, but the delayed peak of GBP antiepileptic effects in animal models, compared to the peak in plasma levels 2 suggests that they may play an important contribute to the therapeutic effect of the drug.
GBP inhibits voltage-dependent sodium currents and binds to a calcium channel in the brain 3 , but the relevance of this actions to GBP anticonvulsant effects has still to be clarified. Three pivotal, placebo-controlled, add-on trials 4-6 demonstrated a dose-response effect at dosages ranging from 600 to 1.800 mg/day suggesting increasing efficacy with increasing dose. In postapproval clinical studies, the efficacy and safety of high GBP dosages was investigated both as long-term and short-term treatment. The drug was well tolerated at all dosages, up to 4800 mg/day and a higher percentage of patients, compared to early studies, reached either satisfactory or complete seizure control [7] [8] [9] [10] .
Pharmacokinetic studies 11, 12 have shown that GBP plasma concentrations are essentially proportional to dosages up to 1800 mg daily, above which they still increase, but not in a linear way 13, 14 .
GBP plasma concentrations have also been measured in several clinical studies. Sivenius et al. 15 found a correlation between efficacy and serum levels starting at GBP concentration of 2 µg/ml, while a similar correlation was not found in other studies 8, 9 . A steady, even if not linear, increase in plasma levels with increasing dosages, up to 6000 mg/day, was found in all the studies where GBP plasma levels have been measured 7-9, 15, 16 .
A drawback in the pharmacokinetic profile of GBP is its short half-life, which suggests the need for thrice daily (T.I.D.) administration which can decrease patient compliance, especially when the drug is used as an add-on to other AEDs.
Empirically, however, in clinical practice, GBP is often administered twice daily (B.I.D.), but no studies have been performed so far to explore whether the switch from T.I.D. to B.I.D. administration causes a decrease in efficacy or a worsening of side-effects due to higher individual doses.
The aim of our study was to verify the feasibility of this switch in a selected population of patients and to assess trough GBP plasma levels under the two different schedules of administration.
MATERIALS AND METHODS

Selection criteria and study design
This study adopted a single centre, add-on, open design.
In a previous, multicentre study, whose results have been reported in abstract form 17 , we selected 171 patients, aged at least 12 years, with definite partial epilepsy, and persistent simple and complex partial seizures with or without secondary generalization, already in therapy with 1 or more AEDs in an adequate dose.
A retrospective three-months baseline period was obtained in all the patients in order to assess a baseline seizure frequency, and then GBP given T.I.D. was added into their current AED therapy.
Out of this sample, we selected 29 stable responders (>50% reduction in seizure frequency versus baseline after GBP add-on), and in whom the dose they were currently taking was considered as their optimal GBP therapeutic dose.
The number of seizures/month, assessed during the three-month period before GBP introduction, was considered as baseline.
The optimal GBP dose was administered with a T.I.D. regimen for three months: patients registered all their seizures and any adverse drug reactions in a daily diary. Thereafter the patients were switched to receive the same dose of GBP with a B.I.D. regimen and followed for another three months period.
Trough plasma levels gabapentin
Concentrations of GBP in plasma were determined at the end of the first month of each T.I.D. and B.I.D. period and trough levels were calculated. GBP concentrations were measured by gas chromatography-mass spectrometry 18 . The concentration of gabapentin was obtained using a calibration curve constructed with the peak area ratio between gabapentin (m/z 210) and internal standard, 5α-cholestane (m/z 217). The calibration curve showed a good linearity from 0.5 to 15 µg/ml (y = 0.314x + 0.131, r = 0.986). The lower limit of detection is 0.08 µg/ml (signal/noise ratio 5 : 1). Imprecision was calculated by multiple measurements of gabapentin (n = 10) on the same day and on different days and the coefficients of variation resulted respectively in 4.8% and 7.3% for concentration ranging between 1 and 8 µg/ml.
Data analysis
Due to small data sets, for which assumptions about the distribution of the variables being analysed and about the homogeneity of variances cannot be validated adequately, distribution free statistical methods have been chosen for the analysis.
Two tailed tests were used for the statistical analysis at a level of significance fixed at α = 0.05.
All the variables were analysed descriptively by means of the usual methods: mean, standard deviation, minimum and maximum, absolute and relative frequencies.
The effect of the GBP introduction on the monthly seizure frequency, either T. 
RESULTS
Twenty-nine patients were enrolled and all finished the study. There were 14 males and 15 females, mean age 37.8 years (range 16-64). Twenty-five patients (86%) had simple and complex partial seizures only and 4 (14%) had secondarily generalized seizures as well. The mean disease duration was 12.8 years. The optimal mean daily dose of GBP was 2117.2 mg (range 1200-3200 mg/day). All patients were on polypharmacy. The mean number of concomitant AED was 1.7, 10 patients received 1 concomitant AED and 19 received 2 concomitant AEDs. The most frequently prescribed concomitant AED was carbamazepine (24 patients), followed by phenobarbitone (12 patients), phenytoin (6 patients), valproic acid (3 patients), lamotrigine (2 patients) and vigabatrin (1 patient). Table 1 reports GBP dose, trough GBP plasma levels, mean monthly seizure frequency and side-effects at baseline, during the T.I.D. and B.I.D. periods for each patient.
The mean number of seizures/month was 4.2 ± 1.9 SD at baseline, 1.0 ± 1. Mean trough plasma levels of GBP did not change significantly from the T.I.D. period (5.4 ± 1.9 µg/ml) to the B.I.D. period (5.1 ± 1.8 µg/ml) (T Test, P = 0.72; C.I. 95% of the difference: −0.41, 0.59) and ranged from 3.2 µg/ml to 6.9 µg/ml in the T.I.D. period and from 3.6 µg/ml to 6.3 µg/ml in the B.I.D. period (Fig. 1) .
Twelve side-effects were reported by 11 patients during the B.I.D. period and 6 side-effects were reported by 5 patients during the T.I.D. period (χ 2 , P = 0.141). The most frequently reported side-effect during both periods was sedation.
DISCUSSION
In this study we assessed the effect of switching GBP administration from a T.I.D. schedule to a B.I.D. schedule upon monthly seizure rate, side-effects and trough GBP plasma levels.
We decided to make the switch in 29 patients who were known stable GBP responders, so that the optimal therapeutic GBP dose had already been found and any possible effect related just to the switch could be more easily detected.
GBP has been approved for T.I.D. administration because of its short half-life; moreover, if a high daily dose is divided in two instead of three single doses, absorption could decrease, thus impairing the achievement of adequate plasma levels or, if absorption is maintained, single doses could become too high, causing more side-effects. Hypothetical consequences of such a switch could be either an increase in seizure frequency or the worsening of side-effects.
The two different administration schedules were examined over a three months period, which can be considered sufficient to detect a possible change in seizure rate or in side-effects due to different GBP plasma levels.
The results of our study did not show any difference in the considered parameters between the two administration regimens.
What is more important in our results is that efficacy in seizure control was maintained without an increase in side-effects and independently of plasma levels. These results confirm the possibility of titrating GBP doses without checking plasma levels, which are unpredictive of response, and suggest that GBP can be administered B.I.D. as safely and effective as T.I.D. with possible advantage to patient compliance.
